Regulatory compliance
The TGA monitors and enforces regulatory compliance in relation to therapeutic goods. This supports consumer protection and a fair market for industry.
Latest alerts
- EVE Allylisopropylacetylurea tabletsThe TGA is warning consumers against taking EVE branded products that contain allylisopropylacetylurea (apronal) as they pose a significant health risk and are prohibited from sale, supply or use in Australia.
- Counterfeit semaglutide vialsThe TGA has detected fake semaglutide, also known as Ozempic, being illegally imported into Australia.
Latest articles
- TGA targets unlawful importation of prescription medicinesThe TGA has issued 5 infringement notices to 3 health practitioners for the alleged unlawful importation of unregistered prescription-only medicines.
- Infringement notices totalling $66,600 given to three Sydney-based companies and two individuals for alleged unlawful importation of nicotine vaping productsThe TGA has issued nine infringement notices to three companies and two associated individuals for the alleged unlawful importation of nicotine vaping products.
- Changes to medical device essential principles for nanomaterialsEssential principle 7 now mentions nanomaterials explicitly (see EP 7.7)
Latest publications
- Therapeutic Goods Advertising and Compliance Education Plan 2023This plan outlines the compliance and education priorities of the Therapeutic Goods Administration for 2023.
- Therapeutic goods advertising compliance: 2021-22 Annual ReportOverview of therapeutic goods advertising complaints handling and compliance for 2021-22
- International Coalition of Medicines Regulatory Authorities (ICMRA)Updates to the ICMRA landing page detailing ICMRA's projects and their role during the COVID-19 pandemic.